OBJECTIVES: To present our experience with the long-term preventive effect of immunotherapy with Uro-Vaxom® on recurrent urinary tract infections (UTI) in adult patients. MATERIALS AND METHODS: Retrospective analysis of 79 patients with recurrent UTI treated with Uro-Vaxom. Recurrent UTIs were defined as ≥ 2 infections in 6 months or ≥ 3 in 12 months. Patients received a 6 mg Uro-Vaxom capsule daily for 90 days followed by discontinuation for 3 months and then administration for the first 10 days of subsequent months 7, 8 and 9 as a 'booster' regime. The primary outcome measure was the number of UTIs encountered in the 12 months pre-treatment compared to 12 months post-treatment. RESULTS: There was a significant decrease in the mean number of UTIs in the year following initiation of Uro-Vaxom® compared to the year preceding administration 3.14 versus 1.53 (p < 0.05) respectively. CONCLUSION: Uro-Vaxom represents a safe and effective treatment option for prophylaxis of recurrent UTIs. In the UK, Uro-Vaxom is currently unlicensed. This study adds to a growing body of evidence in favor of non-antibiotic immune-prophylaxis for recurrent UTI.
OBJECTIVES: To present our experience with the long-term preventive effect of immunotherapy with Uro-Vaxom® on recurrent urinary tract infections (UTI) in adult patients. MATERIALS AND METHODS: Retrospective analysis of 79 patients with recurrent UTI treated with Uro-Vaxom. Recurrent UTIs were defined as ≥ 2 infections in 6 months or ≥ 3 in 12 months. Patients received a 6 mg Uro-Vaxom capsule daily for 90 days followed by discontinuation for 3 months and then administration for the first 10 days of subsequent months 7, 8 and 9 as a 'booster' regime. The primary outcome measure was the number of UTIs encountered in the 12 months pre-treatment compared to 12 months post-treatment. RESULTS: There was a significant decrease in the mean number of UTIs in the year following initiation of Uro-Vaxom® compared to the year preceding administration 3.14 versus 1.53 (p < 0.05) respectively. CONCLUSION: Uro-Vaxom represents a safe and effective treatment option for prophylaxis of recurrent UTIs. In the UK, Uro-Vaxom is currently unlicensed. This study adds to a growing body of evidence in favor of non-antibiotic immune-prophylaxis for recurrent UTI.
Authors: Kun Suk Kim; Ji-Yoon Kim; In Gab Jeong; Jae-Seung Paick; Hwancheol Son; Dae Jung Lim; Hong Bang Shim; Won Hee Park; Hee Chang Jung; Myung-Soo Choo Journal: J Korean Med Sci Date: 2010-02-17 Impact factor: 2.153
Authors: Zafer Tandogdu; Mete Cek; Florian Wagenlehner; Kurt Naber; Peter Tenke; Edgar van Ostrum; Truls Bjerklund Johansen Journal: World J Urol Date: 2013-08-24 Impact factor: 4.226
Authors: María F Lorenzo-Gómez; Bárbara Padilla-Fernández; María B García-Cenador; Álvaro J Virseda-Rodríguez; Isidoro Martín-García; Alfonso Sánchez-Escudero; Manuel J Vicente-Arroyo; José A Mirón-Canelo Journal: Front Cell Infect Microbiol Date: 2015-06-03 Impact factor: 5.293
Authors: Alexis Laurent; Philippe Abdel-Sayed; Corinne Scaletta; Philippe Laurent; Elénie Laurent; Murielle Michetti; Anthony de Buys Roessingh; Wassim Raffoul; Nathalie Hirt-Burri; Lee Ann Applegate Journal: Bioengineering (Basel) Date: 2021-12-17